BLVIS A Blue Vision A

Passing of the General Meeting of Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S

  
  
 Passing of the General Meeting of Pharma Equity Group A/S
  



16 April 2024

Company Announcement no. 13



 

Pharma Equity Group A/S today held its Annual General Meeting with the following results:



1) The board of directors' report on the Company's activities in the past year was noted by the General Meeting



2) The audited annual report was approved



3) The executive board and the board of directors was discharged from liability



4) Appropriation of profit or loss as proposed by the board of directors was adopted



5) The remuneration report 2023 for an advisory vote was approved



6) The remuneration to the board of directors for the current financial year was approved



  • The chair of the board of directors receives DKK 350,000.
  • The deputy chair of the board of directors receives DKK 250,000.
  • Members of the board of directors receive DKK 150,000.






  • Members of the board of directors' audit committee, the nomination- and remuneration committee or other committees receive a remuneration of DKK 25,000 in total for all committee work. This does not apply to the chair or the deputy chair of the board of directors, who does not receive additional remuneration.
 7) Election of the board of directors

 



The following board members was re-elected: Christian Vinding Thomsen, Martin Engell-Rossen, Omar S. Qandeel, Lars Gundorph and Peter Vilmann.



 

The board constituted itself the following way after the General Meeting: Christian Vinding Thomsen (chair), Martin Engell-Rossen (deputy chair), Omar S. Qandeel, Lars Gundorph and Peter Vilmann.



 

8) BDO STATSAUTORISERET REVISIONSAKTIESELSKAB (“BDO”), Havneholmen 29, 1561 København V, CVR no. 20222670 was elected as the Company’s auditor.



9) The following proposals from the board of directors were approved:



  1. Proposal to increase the authorization to issue new shares with pre-emption rights (article 4.1.A)
  2. Proposal to combine and increase the two separate authorizations to issue new shares without pre-emption rights and grant a one-year extension of the new combined authorization (articles 4.1.B and 4.1.C)
  3. Proposal to grant a one-year extension of the authorization to issue warrants (article 4.2)
  4. Proposal to increase the authorization to issue convertible loan notes (article 4.3.A)
10) The chair of the general meeting, with a right of substitution, was authorized to file the resolutions adopted with the Danish Business Authority and to make any such amendments as the Danish Business Authority may require in order to register or approve the resolutions adopted. 



For further information, please contact:



 
 Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone:



Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone:
  



About Pharma Equity Group A/S



Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.



The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.



 



 

Attachment



EN
16/04/2024

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Forløb af generalforsamlingen i Pharma Equity Group A/S

Forløb af generalforsamlingen i Pharma Equity Group A/S Forløb af generalforsamlingen i Pharma Equity Group A/S 17. april 2026Selskabsmeddelelse nr. 5 Den 16. april 2026 kl. 15.30 blev der afholdt ordinær generalforsamling i Pharma Equity Group A/S, CVR-nr. 26791413, hos Wihlborgs Kantiner, Slotsmarken 15, 2970 Hørsholm. Selskabets bestyrelsesformand, Christian Vinding Thomsen, indledte generalforsamlingen med at byde velkommen og nævne, at bestyrelsen havde besluttet, at generalforsamlingen skulle afholdes på dansk og at bestyrelsen havde foreslået Christian Vinding Thomsen som dirigen...

April 17, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Proceedings of the Annual General Meeting of Pharma Equity Group A/S

Proceedings of the Annual General Meeting of Pharma Equity Group A/S Proceedings of the Annual General Meeting of Pharma Equity Group A/S 17 April 2026Company Announcement no. 5 Pharma Equity Group A/S held its annual general meeting on 16 April 2026 at 3:30 pm CEST at Wihlborgs Kantiner, Slotsmarken 15, DK-2970 Hørsholm. The Chairman of the Board of Directors, Christian Vinding Thomsen, welcomed the shareholders and informed the meeting that the Board of Directors had resolved that the general meeting be conducted in Danish and had proposed Christian Vinding Thomsen as chair of the meet...

April 17, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S

Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S 25. marts 2026 Meddelelse nr. 4 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S (“PEG” eller “Selskabet”) den: 16. april 2026, kl. 15:30 på adressen Wihlborgs KantinerSlotsmarken 152970 Hørsholm Dagsordenen for den ordinære generalforsamling er følgende: Bestyrelsens beretning om Selskabets virksomhed det forløbne årFremlæggelse af revideret årsrapport til godkendelseMeddelelse af decharge for bestyrelsen og...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Notice convening the annual general meeting in Pharma Equity Group A/S

Notice convening the annual general meeting in Pharma Equity Group A/S 25 March 2026 Announcement no. 4 Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma Equity Group A/S (“PEG” or the “Company”) to be held on: 16 April 2026, at 3.30 PM CEST at Wihlborgs CanteensSlotsmarken 15DK-2970 Hørsholm The agenda for the annual general meeting is as follows: The board of directors' report on the Company's activities in the past yearPresentation of the audited annual report for approvalDischarge to...

March 25, 2026 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S - Årsrapport 2025

Pharma Equity Group A/S - Årsrapport 2025 25 March 2026 Announcement no. 3 Pharma Equity Group A/S - Årsrapport 2025 Pharma Equity Group A/S - Årsrapport 2025 - året i hovedtræk Bestyrelsen for Pharma Equity Group A/S har dags dato behandlet og godkendt Selskabets årsrapport for 2025, som i hovedtræk kan sammenfattes som følger: Reponex Pharmaceuticals A/S har i 2025 opnået myndighedsgodkendelse til at igangsætte et pivotalt fase 2-studie med RNX-011 til behandling af sekundær bakteriel bughindebetændelse.RNX-051 er i 2025 blevet videreudviklet gennem fortsat udviklingsarbejde, yderlig...

March 25, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch